about
Early versus delayed erythropoietin for the anaemia of end-stage kidney diseasePharmacological treatments for fatigue associated with palliative careEarly versus delayed erythropoietin for the anaemia of end-stage kidney diseaseErythropoiesis-stimulating agents for anemia in rheumatoid arthritisErythropoiesis-stimulating agents for anemia in rheumatoid arthritisErythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis.Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection.Oncolytic Poxviruses.Erythropoietin and erythropoietin receptor in hepatocellular carcinoma: correlation with vasculogenic mimicry and poor prognosis.Risk management of biosimilars in oncology: each medicine is a work in progress.Erythropoietin Stimulates Tumor Growth via EphB4.Pharmacological activation of lysophosphatidic acid receptors regulates erythropoiesisPhagocyte respiratory burst activates macrophage erythropoietin signalling to promote acute inflammation resolution.Today's challenges in pharmacovigilance: what can we learn from epoetins?Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy.Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments.Fighting insomnia and battling lethargy: the yin and yang of palliative care.Erythropoietin-stimulating agents and clinical outcomes in metastatic breast cancer patients with chemotherapy-induced anemia: a closed debate?Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis.Vaccinia virus-mediated expression of human erythropoietin in tumors enhances virotherapy and alleviates cancer-related anemia in mice.Erythrocytosis in hepatocellular carcinoma portends poor prognosis by respiratory dysfunction secondary to mitochondrial DNA mutations.A novel synthetic derivative of human erythropoietin designed to bind to glycosaminoglycans.Lysophosphatidic acid induces erythropoiesis through activating lysophosphatidic acid receptor 3.
P2860
Q24187089-1FBCB25B-C2E2-4F53-A435-FEE13065AEEFQ24187756-294EBB10-0C49-47C8-973F-56C8E9775A3BQ24194838-6AF7417C-6CC8-444D-B4BE-993DE69C6113Q24200775-9276784A-0C8F-4D2D-9E16-21F7C92B8DC8Q24234260-F7B30888-A6E0-49A3-8B28-BE07EC01A628Q33827405-67B943A4-5C22-491C-B0E0-2F467CADBD19Q35113272-30DF7022-1B3F-4FF5-A88B-C4628077912AQ35234349-974483B3-98E3-4B9C-AD7A-91CFA729EEB3Q35741127-2F8E7D27-FAA3-4234-90A6-9BFB452C15C0Q35795287-5118F1C2-AC1E-4BDA-AB23-D0844E8413BFQ36275814-FC999BD9-FCAA-45CB-8331-8F1B9ED6FF9FQ36950604-38885B02-B531-4106-9D47-4B9024224FF7Q37089046-ADADAAAD-9096-41A3-9110-4F339761ED4FQ37854580-CEB4F42C-A800-4C22-85A9-F28B16FCB71BQ37982120-4C916379-A7BE-49D8-8A8A-B5CE931CF697Q37999380-6C5352D7-D480-4654-BAA9-2F056591DAFCQ38188834-17CE6F15-DD98-4E61-8FF2-97714CABB299Q38189738-0855F337-E325-42AF-9885-7C1566939D6DQ39069010-FC093953-49A3-4901-9F3C-39FF9AB4537BQ39139854-2594AABC-62B5-4E93-8E02-D964A87DC2A9Q39256165-2495E28E-1648-435D-B660-298F49D57AF6Q39340642-4831342F-0F2A-4CD3-8843-1017BC293843Q42726886-EACCD883-18FE-453D-99EA-DA21FF749C22
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Erythropoietin in cancer patients.
@en
Erythropoietin in cancer patients.
@nl
type
label
Erythropoietin in cancer patients.
@en
Erythropoietin in cancer patients.
@nl
prefLabel
Erythropoietin in cancer patients.
@en
Erythropoietin in cancer patients.
@nl
P1476
Erythropoietin in cancer patients.
@en
P2093
John A Glaspy
P304
P356
10.1146/ANNUREV.MED.60.050307.110718
P577
2009-01-01T00:00:00Z